Zhou, Q <br/><br/>
Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy.  [electronic resource] 

 -  Clinical and experimental immunology  Jul 2013 
 - 131-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>1365-2249 
<br/><br/><label>Standard No.: </label>10.1111/cei.12095  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal, Humanized--pharmacology<br/>Antibodies, Monoclonal, Murine-Derived--pharmacology<br/>Antibody-Dependent Cell Cytotoxicity--drug effects<br/>Antigens, Surface--metabolism<br/>Antineoplastic Agents--pharmacology<br/>CD3 Complex--metabolism<br/>Cell Degranulation--drug effects<br/>Cell Line, Tumor<br/>Cetuximab<br/>Coculture Techniques<br/>Cytokines--blood<br/>Dipeptides--pharmacology<br/>Down-Regulation--drug effects<br/>GPI-Linked Proteins--metabolism<br/>Humans<br/>Killer Cells, Natural--drug effects<br/>Lymphocyte Activation--drug effects<br/>Matrix Metalloproteinase Inhibitors--pharmacology<br/>Matrix Metalloproteinases--physiology<br/>Phosphorylation--drug effects<br/>Protein Processing, Post-Translational--drug effects<br/>Receptors, IgG--metabolism<br/>Rituximab<br/>Signal Transduction--drug effects<br/>Trastuzumab